In France, the semaglutide 2.4-mg (Wegovy) was part of an early-access initiative from July 2022 to September 2023
Get Prior Authorization: Your provider will submit medical records, diagnosis codes, and treatment history to justify why you need the medication
Davies M, Frch L, Jeppesen OK et al (2021) Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Headaches : Mild headaches are possible, especially in the first few weeks
Participants with class III obesity (BMI 40 or higher) were more likely to be late responders, meaning they needed more time to achieve significant weight loss